G.D. Kotzalidis, A. Facchi, L. Tarsitani, V. Mantua, P.P. Colombo, P. Pancheri - Vol. 7, Giugno 2001, num.2
Testo Immagini Bibliografia Summary Riassunto Indice
Thalamic abnormalities in schizophrenia
Anomalie talamiche nella schizofrenia
1 Parigi S, Ferro-Milone F. Talamo e affettività. Osservazioni
nell'uomo mediante stimolazioni e demolizioni con metodo stereotassico.
Riv Neurobiol 1966;12:10-7.
2 Poblete M, Palestini M, Figueroa E, Gallardo R, Rojas J, Covarrubias MI,
et al. Stereotaxic thalamotomy (lamella medialis) in aggressive psychiatric
patients. Confin Neurol 1970;32:326-31.
3 Heath RG. Correlation of brain function with emotional behavior.
Biol Psychiatry 1976;11:463-80.
4 Flekkoy K. Psychophysiological and neurophysiological aspects of schizophrenia.
Acta Psychiatr Scand 1975;51:234-48.
5 Erdelyi E, Elliott GR, Wyatt RJ, Barchas JD. S-adenosylmethionine-dependent
N-methyltransferase activity in autopsied brain parts of chronic schizophrenics
and controls. Am J Psychiatry 1978;135:725-8.
6 Andreasen NC, Arndt S, Swayze V 2nd, Cizadlo T, Flaum M, O'Leary D, et al.
Thalamic abnormalities in schizophrenia visualized through magnetic resonance
image averaging. Science 1994;266:294-8.
7 Andreasen NC, Ehrhardt JC, Swayze VW 2nd, Alliger RJ, Yuh WT, Cohen G, et
al. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic
significance of structural abnormalities. Arch Gen Psychiatry 1990;47:35-44.
8 Andreasen NC, Swayze V, O'Leary DS, Nopoulos P, Cizadlo T, Harris G, et
al. Abnormalities in midline attentional circuitry in schizophrenia: evidence
from magnetic resonance and positron emission tomography. Eur Neuropsychopharmacol
1995;5:37-41.
9 O'Leary DS, Andreasen NC, Hurtig RR, Kesler ML, Rogers M, Arndt S, et al.
Auditory attentional deficits in patients with schizophrenia. A positron
emission tomography study. Arch Gen Psychiatry 1996;53:633-41.
10 Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto
LL, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits
in neuroleptic-naive patients. Lancet 1997;349:1730-4.
11 Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary DS, Watkins GL, Boles
Ponto LL, et al. Recalling word lists reveals "cognitive dysmetria"
in schizophrenia: a positron emission tomography study. Am J Psychiatry
1999;156:386-92 (comment in: Am J Psychiatry 2000;157:662-3).
12 Andreasen NC. The role of the thalamus in schizophrenia. Can J Psychiatry
1997;42:27-33.
13 Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Ponto LL, et al.
Schizophrenia and cognitive dysmetria: a positron-emission tomography study
of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad
Sci USA 1996;93:9985-90.
14 Andreasen NC, Paradiso S, O'Leary DS. "Cognitive dysmetria"
as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar
circuitry? Schizophr Bull 1998;24:203-18.
15 Feinberg I. Schizophrenia: caused by a fault in programmed synaptic
elimination during adolescence? J Psychiatr Res 1982-83;17:319-34.
16 Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive
synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited.
J Psychiatr Res 1994;28:239-65.
17 Arnold SE, Trojanowski JQ. Recent advances in defining the neuropathology
of schizophrenia. Acta Neuropathol Berl 1996;92:217-31.
18 Bunney BG, Potkin SG, Bunney WE Jr. New morphological and neuropathological
findings in schizophrenia: a neurodevelopmental perspective. Clin Neurosci
1995;3:81-8.
19 Murray RM, Jones P, O'Callaghan E. Fetal brain development and later
schizophrenia. Ciba Found Symp 1991;156:155-63; discussion 163-70.
20 Bloom FE. Advancing a neurodevelopmental origin for schizophrenia.
Arch Gen Psychiatry 1993;50:224-7.
21 Jacobson S, Trojanowski JQ. Corticothalamic neurons and thalamocortical
terminal fields: an investigation in rat using horseradish peroxidase and
autoradiography. Brain Res 1975;85:385-401.
22 Gaspar P, Bloch B, Le Moine C. D1 and D2 receptor gene expression in
the rat frontal cortex: cellular localization in different classes of efferent
neurons. Eur J Neurosci 1995;7:1050-63.
23 Orona E, Gabriel M. Multiple-unit activity of the prefrontal cortex
and mediodorsal thalamic nucleus during acquisition of discriminative avoidance
behavior in rabbits. Brain Res 1983;263:295-312.
24 Preuss TM, Goldman-Rakic PS. Crossed corticothalamic and thalamocortical
connections of macaque prefrontal cortex. J Comp Neurol 1987;257:269-81.
25 Negyessy L, Hamori J, Bentivoglio M. Contralateral cortical projection
to the mediodorsal thalamic nucleus: origin and synaptic organization in the
rat. Neuroscience 1998;84:741-53.
26 Siwek DF, Pandya DN. Prefrontal projections to the mediodorsal nucleus
of the thalamus in the rhesus monkey. J Comp Neurol 1991;312:509-24.
27 Giguere M, Goldman-Rakic PS. Mediodorsal nucleus: areal, laminar, and
tangential distribution of afferents and efferents in the frontal lobe of
rhesus monkeys. J Comp Neurol 1988;277:195-213.
28 Kuroda M, Yokofujita J, Murakami K. An ultrastructural study of the
neural circuit between the prefrontal cortex and the mediodorsal nucleus of
the thalamus. Prog Neurobiol 1998;54:417-58.
29 Portas CM, Goldstein JM, Shenton ME, Hokama HH, Wible CG, Fischer I, et
al. Volumetric evaluation of the thalamus in schizophrenic male patients
using magnetic resonance imaging. Biol Psychiatry 1998;43:649-59.
30 Wolkin A, Rusinek H, Vaid G, Arena L, Lafargue T, Sanfilipo M, et al. Structural
magnetic resonance image averaging in schizophrenia. Am J Psychiatry 1998;155:1064-73.
31 Staal WG, Hulshoff Pol HE, Schnack H, van der Schot AC, Kahn RS. Partial
volume decrease of the thalamus in relatives of patients with schizophrenia.
Am J Psychiatry 1998;155:1784-6.
32 Arciniegas D, Rojas DC, Teale P, Sheeder J, Sandberg E, Reite M. The
thalamus and the schizophrenia phenotype: failure to replicate reduced volume.
Biol Psychiatry 1999;45:1329-35.
33 Dasari M, Friedman L, Jesberger J, Stuve TA, Findling RL, Swales TP, et
al. A magnetic resonance imaging study of thalamic area in adolescent patients
with either schizophrenia or bipolar disorder as compared to healthy controls.
Psychiatry Res 1999;91:155-62.
34 Lawrie SM, Whalley H, Kestelman JN, Abukmeil SS, Byrne M, Hodges A, et
al. Magnetic resonance imaging of brain in people at high risk of developing
schizophrenia. Lancet 1999;353:30-3.
35 Seidman LJ, Faraone SV, Goldstein JM, Goodman JM, Kremen WS, Toomey R,
et al. Thalamic and amygdala-hippocampal volume reductions in first-degree
relatives of patients with schizophrenia: an MRI-based morphometric analysis.
Biol Psychiatry 1999;46:941-54.
36 Pakkenberg B, Gundersen HJ. New stereological method for obtaining unbiased
and efficient estimates of total nerve cell number in human brain areas. Exemplified
by the mediodorsal thalamic nucleus in schizophrenics. APMIS 1989;97:677-81.
37 Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal
thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry
1990;47:1023-8.
38 Pakkenberg B. Leucotomized schizophrenics lose neurons in the mediodorsal
thalamic nucleus. Neuropathol Appl Neurobiol 1993;19:373-80.
39 Gur RE, Cowell PE, Latshaw A, Turetsky BI, Grossman RI, Arnold SE, et al.
Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia.
Arch Gen Psychiatry 2000;57:761-8.
40 Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation
of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998;155:1049-55.
41 Deakin JF, Simpson MD. A two-process theory of schizophrenia: evidence
from studies in post-mortem brain. J Psychiatr Res 1997;31:277-95.
42 Simpson MD, Lubman DI, Slater P, Deakin JF. Autoradiography with [3H]8-OH-DPAT
reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia.
Biol Psychiatry 1996;39:919-28.
43 Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et
al. Physiological dysfunction of the dorsolateral prefrontal cortex in
schizophrenia revisited. Cereb Cortex 2000;10:1078-92.
44 Lewis DA, Gonzalez-Burgos G. Intrinsic excitatory connections in the
prefrontal cortex and the pathophysiology of schizophrenia. Brain Res
Bull 2000;52:309-17.
45 Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al.
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal
cortex and basal ganglia during working memory performance. Biol Psychiatry
2000;48:99-109.
46 Lewis DA. GABAergic local circuit neurons and prefrontal cortical dysfunction
in schizophrenia. Brain Res Rev 2000;31:270-6.
47 Bunney WE, Bunney BG. Evidence for a compromised dorsolateral prefrontal
cortical parallel circuit in schizophrenia. Brain Res Rev 2000;31:138-46.
48 Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal
cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000;57:65-73.
49 Kalus P, Senitz D, Beckmann H. Altered distribution of parvalbumin-immunoreactive
local circuit neurons in the anterior cingulate cortex of schizophrenic patients.
Psychiatry Res 1997;75:49-59.
50 Kalus P, Senitz D, Lauer M, Beckmann H. Inhibitory cartridge synapses
in the anterior cingulate cortex of schizophrenics. J Neural Transm 1999;106:763-71.
51 Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced
in the prefrontal cortex of schizophrenics. Schizophr Res 1997;24:349-55.
52 Woo TU, Miller JL, Lewis DA. Schizophrenia and the parvalbumin-containing
class of cortical local circuit neurons. Am J Psychiatry 1997;154:1013-5.
53 Dixon G, Dissanaike S, Harper CG. Parvalbumin-immunoreactive neurons
in the human anteroventral thalamic nucleus. Neuroreport 2000;11:97-101.
54 Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal
lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience
1995;69:339-43.
55 Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in
the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic
specificity. Arch Gen Psychiatry 1997;54:943-52.
56 Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and
plasticity-associated proteins in anterior frontal cortex in severe mental
illness. Neuroscience 1999;91:1247-55.
57 Glantz LA, Austin MC, Lewis DA. Normal cellular levels of synaptophysin
mRNA expression in the prefrontal cortex of subjects with schizophrenia.
Biol Psychiatry 2000;48:389-97.
58 Eastwood SL, Cairns NJ, Harrison PJ. Synaptophysin gene expression in
schizophrenia. Investigation of synaptic pathology in the cerebral cortex.
Br J Psychiatry 2000;176:236-42.
59 Landen M, Grenfeldt B, Davidsson P, Stridsberg M, Regland B, Gottfries
CG, et al. Reduction of chromogranin A and B but not C in the cerebrospinal
fluid in subjects with schizophrenia. Eur Neuropsychopharmacol 1999;9:311-5.
60 Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. Levels of mRNAs
encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal
cortex of elderly schizophrenic patients. Biol Psychiatry 2000;48:184-96.
61 Popken GJ, Bunney WE Jr, Potkin SG, Jones EG. Subnucleus-specific loss
of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA
2000;97:9276-80.
62 Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus
and caudate of elderly patients with schizophrenia. Psychiatry Res 2000;93:103-10.
63 Young KA, Manaye KF, Liang C, Hicks PB, German DC. Reduced number of
mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry
2000;47:944-53.
64 Pakkenberg B. The volume of the mediodorsal thalamic nucleus in treated
and untreated schizophrenics. Schizophr Res 1992;7:95-100.
65 Danos P, Baumann B, Bernstein HG, Franz M, Stauch R, Northoff G, et al.
Schizophrenia and anteroventral thalamic nucleus: selective decrease of
parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry
Res 1998;82:1-10.
66 Davidsson P, Gottfries J, Bogdanovic N, Ekman R, Karlsson I, Gottfries
CG, et al. The synaptic-vesicle-specific proteins rab3a and synaptophysin
are reduced in thalamus and related cortical brain regions in schizophrenic
brains. Schizophr Res 1999;40:23-9.
67 Blennow K, Bogdanovic N, Heilig M, Grenfeldt B, Karlsson I, Davidsson P.
Reduction of the synaptic protein rab3a in the thalamus and connecting
brain regions in post-mortem schizophrenic brains. J Neural Transm 2000;107:1085-97.
68 Blennow K, Davidsson P, Gottfries C-G, Ekman R, Heilig M. Synaptic degeneration
in thalamus in schizophrenia (letter). Lancet 1996;348:692-3.
69 Landén M, Davidsson P, Gottfries CG, Grenfeldt B, Stridsberg M,
Blennow K. Reduction of the small synaptic vesicle protein synaptophysin
but not the large dense core chromogranins in the left thalamus of subjects
with schizophrenia. Biol Psychiatry 1999;46:1698-702.
70 Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, et al. Neuronal
nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin
and nicotine binding in the thalamus. J Neurochem 1999;73:1590-7.
71 Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff
JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic
thalamus. Biol Psychiatry 2000;47:22-8.
72 Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff
JH. Ionotropic glutamate receptor binding and subunit mRNA expression in
thalamic nuclei in schizophrenia. Am J Psychiatry 2000;157:1811-23.
73 Omori M, Murata T, Kimura H, Koshimoto Y, Kado H, Ishimori Y, et al. Thalamic
abnormalities in patients with schizophrenia revealed by proton magnetic resonance
spectroscopy. Psychiatry Res 2000;98:155-62.
74 Deicken RF, Johnson C, Eliaz Y, Schuff N. Reduced concentrations of
thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiatry
2000;157:644-7.
75 Rodriguez VM, Andree RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL,
et al. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory
schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res 1997;76:51-61.
76 Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, et
al. Three-dimensional analysis with MRI and PET of the size, shape, and
function of the thalamus in the schizophrenia spectrum. Am J Psychiatry
1999;156:1190-9.
77 Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A, et al. PET
and MRI of the thalamus in never-medicated patients with schizophrenia.
Am J Psychiatry 1996;153:191-9.
78 Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr
JB, et al. Cortical-striatal-thalamic circuits and brain glucose metabolic
activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry
1993;150:1325-36.
79 Kim JJ, Mohamed S, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL,
et al. Regional neural dysfunctions in chronic schizophrenia studied with
positron emission tomography. Am J Psychiatry 2000;157:542-8.
80 Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic
resonance spectroscopy of the brain in schizophrenic and affective patients.
Schizophr Res 1992;8:43-9.
81 Nasrallah HA, Skinner TE, Schmalbrock P, Robitaille PM. Proton magnetic
resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia:
a pilot study. Br J Psychiatry 1994;165:481-5.
82 Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al.
Regionally specific pattern of neurochemical pathology in schizophrenia
as assessed by multislice proton magnetic resonance spectroscopic imaging.
Am J Psychiatry 1996;153:1554-63.
83 Fujimoto T, Nakano T, Takano T, Takeuchi K, Yamada K, Fukuzako T, et al.
Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia.
Biol Psychiatry 1996;40:14-8.
84 Eluri R, Paul C, Roemer R, Boyko O. Single-voxel proton magnetic resonance
spectroscopy of the pons and cerebellum in patients with schizophrenia: a
preliminary study. Psychiatry Res 1998;84:17-26.
85 Yurgelun-Todd DA, Renshaw PF, Gruber SA, Ed M, Waternaux C, Cohen BM. Proton
magnetic resonance spectroscopy of the temporal lobes in schizophrenics and
normal controls. Schizophr Res 1996;19:55-9.
86 Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance spectroscopy
in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia.
Neuropsychopharmacology 1999;20:131-40.
87 Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic resonance spectroscopy
of the anterior cingulate region in schizophrenia. Schizophr Res 1997;27:65-71.
88 Buckley PF, Moore C, Long H, Larkin C, Thompson P, Mulvany F, et al. 1H-magnetic
resonance spectroscopy of the left temporal and frontal lobes in schizophrenia:
clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatry
1994;36:792-800.
89 Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW. Decreased left
frontal lobe N-acetylaspartate in schizophrenia. Am J Psychiatry 1997;154:688-90.
90 Delamillieure P, Fernandez J, Constans JM, Brazo P, Benali K, Abadie P,
et al. Proton magnetic resonance spectroscopy of the medial prefrontal
cortex in patients with deficit schizophrenia: preliminary report. Am
J Psychiatry 2000;157:641-3.
91 Bertolino A, Kumra S, Callicott JH, Mattay VS, Lestz RM, Jacobsen L, et
al. Common pattern of cortical pathology in childhood-onset and adult-onset
schizophrenia as identified by proton magnetic resonance spectroscopic imaging.
Am J Psychiatry 1998;155:1376-83.
92 Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, et al.
An in vivo proton magnetic resonance spectroscopy study of schizophrenia
patients. Schizophr Bull 1996;22:597-609.
93 Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al.
Measurement of glutamate and glutamine in the medial prefrontal cortex
of never-treated schizophrenic patients and healthy controls by proton magnetic
resonance spectroscopy. Arch Gen Psychiatry 1997;54:959-65.
94 Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, et
al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate
and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology
2000;22:125-32.
95 Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA,
et al. Specific relationship between prefrontal neuronal N-acetylaspartate
and activation of the working memory cortical network in schizophrenia.
Am J Psychiatry 2000;157:26-33.
96 Callicott JH, Ramsey NF, Tallent K, Bertolino A, Knable MB, Coppola R,
et al. Functional magnetic resonance imaging brain mapping in psychiatry:
methodological issues illustrated in a study of working memory in schizophrenia.
Neuropsychopharmacology 1998;18:186-96.
97 Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining
the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms.
Biol Psychiatry 1999;46:908-20.
98 Gaser C, Volz HP, Kiebel S, Riehemann S, Sauer H. Detecting structural
changes in whole brain based on nonlinear deformations-application to schizophrenia
research. Neuroimage 1999;10:107-13.
99 Jones EG. Cortical development and neuropathology in schizophrenia.
Ciba Found Symp 1995;193:277-95.
100 Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA,
et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase
cells in frontal lobe of schizophrenics implies disturbances of cortical development.
Arch Gen Psychiatry 1993;50:169-77.
101 Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG. Maldistribution
of interstitial neurons in prefrontal white matter of the brains of schizophrenic
patients. Arch Gen Psychiatry 1996;53:425-36.
102 Somogyi P, Tamas G, Lujan R, Buhl EH. Salient features of synaptic
organisation in the cerebral cortex. Brain Res Rev 1998;26:113-35.
103 Shatz CJ. How are specific connections formed between thalamus and
cortex? Curr Opin Neurobiol 1992;2:78-82.
104 Adams NC, Lozsadi DA, Guillery RW. Complexities in the thalamocortical
and corticothalamic pathways. Eur J Neurosci 1997;9:204-9.
105 Molnar Z, Blakemore C. How do thalamic axons find their way to the
cortex? Trends Neurosci 1995;18:389-97.
106 Yan YH, van Brederode JF, Hendrickson AE. Developmental changes in
calretinin expression in GABAergic and nonGABAergic neurons in monkey striate
cortex. J Comp Neurol 1995;363:78-92.
107 Kalus P, Senitz D, Beckmann H. Cortical layer I changes in schizophrenia.
J Neural Transm 1997;104:549-59.
108 Soria JM, Fairen A. Cellular mosaics in the rat marginal zone define
an early neocortical territorialization. Cereb Cortex 2000;10:400-12.
109 Molnar Z, Knott GW, Blakemore C, Saunders NR. Development of thalamocortical
projections in the South American gray short-tailed opossum (Monodelphis domestica).
J Comp Neurol 1998;398:491-514.
110 Molnar Z, Adams R, Blakemore C. Mechanisms underlying the early establishment
of thalamocortical connections in the rat. J Neurosci 1998;18:5723-45.
111 van Eden CG, Rinkens A, Uylings HB. Retrograde degeneration of thalamic
neurons in the mediodorsal nucleus after neonatal and adult aspiration lesions
of the medial prefrontal cortex in the rat. Implications for mechanisms of
functional recovery. Eur J Neurosci 1998;10:1581-9.
112 Tienari P, Lahti I, Sorri A, Naarala M, Moring J, Wahlberg KE, et al.
The Finnish adoptive family study of schizophrenia. J Psychiatr Res
1987;21:437-45.
113 Wahlberg KE, Wynne LC, Oja H, Keskitalo P, Anais-Tanner H, Koistinen P,
et al. Thought disorder index of Finnish adoptees and communication deviance
of their adoptive parents. Psychol Med 2000;30:127-36.
114 Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr J. Saccadic
eye movement abnormalities in relatives of patients with schizophrenia.
Schizophr Res 2000;45:235-44.
115 Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation
of the startle response and startle laterality in relatives of schizophrenic
patients and in subjects with schizotypal personality disorder: evidence of
inhibitory deficits. Am J Psychiatry 2000;157:1660-8.
116 Blackwood DH, Glabus MF, Dunan J, O'Carroll RE, Muir WJ, Ebmeier KP. Altered
cerebral perfusion measured by SPECT in relatives of patients with schizophrenia.
Correlations with memory and P300. Br J Psychiatry 1999;175:357-66.
117 Laurent A, Saoud M, Bougerol T, d'Amato T, Anchisi AM, Biloa-Tang M, et
al. Attentional deficits in patients with schizophrenia and in their non-psychotic
first-degree relatives. Psychiatry Res 1999;89:147-59.
118 Conklin HM, Curtis CE, Katsanis J, Iacono WG. Verbal working memory
impairment in schizophrenia patients and their first-degree relatives: evidence
from the digit span task. Am J Psychiatry 2000;157:275-7.
119 Kendler KS, Gruenberg AM, Kinney DK. Independent diagnoses of adoptees
and relatives as defined by DSM-III in the provincial and national samples
of the Danish Adoption Study of Schizophrenia. Arch Gen Psychiatry 1994;51:456-68.
120 Kety SS. Schizophrenic illness in the families of schizophrenic adoptees:
findings from the Danish national sample. Schizophr Bull 1988;14:217-22.
121 Burgeois M. L'adoption et ses aspects psychiatriques. Ann Med Psychol
(Paris) 1975;2:73-103.
122 Eldred CA, Rosenthal D, Wender PH, Kety SS, Schulsinger F, Welner J, et
al. Some aspects of adoption in selected samples of adult adoptees.
Am J Orthopsychiatry 1976;46:279-90.
123 Tienari P, Sorri A, Lahti I, Naarala M, Wahlberg KE, Pohjola J, et al.
Interaction of genetic and psychosocial factors in schizophrenia. Acta
Psychiatr Scand 1985;319:19-30.
124 Ingraham LJ, Kety SS. Adoption studies of schizophrenia. Am J Med
Genet 2000;97:18-22.
125 Slotnick BM, Kaneko N. Role of mediodorsal thalamic nucleus in olfactory
discrimination learning in rats. Science 1981;214:91-2.
126 Mukhin EI. Rol’ mediodorzal’nogo iadra talamusa v funktsii obobshhceniia
u koshek [Role of the mediodorsal nucleus of the thalamus in the function
of generalization in the cat]. Zh Vyssh Nerv Deiat Im I P Pavlova 1985;35:449-56.
127 Barbas H. Connections underlying the synthesis of cognition, memory,
and emotion in primate prefrontal cortices. Brain Res Bull 2000;52:319-30.
128 Gaffan D, Parker A. Mediodorsal thalamic function in scene memory in
rhesus monkeys. Brain 2000;123:816-27.
129 Van der Werf YD, Witter MP, Uylings HB, Jolles J. Neuropsychology of
infarctions in the thalamus: a review. Neuropsychologia 2000;38:613-27.
130 Buchanan SL, Penney J, Tebbutt D, Powell DA. Lesions of the mediodorsal
nucleus of the thalamus and classical eyeblink conditioning under less-than-optimal
stimulus conditions: role of partial reinforcement and interstimulus interval.
Behav Neurosci 1997;111:1075-85.
131 Cassidy RM, Gale K. Mediodorsal thalamus plays a critical role in the
development of limbic motor seizures. J Neurosci 1998;18:9002-9.
132 Halliday G, Cullen K, Harding A. Neuropathological correlates of memory
dysfunction in the Wernicke-Korsakoff syndrome. Alcohol 1994;2:245-51.
133 Murasaki M. Role of the mediodorsal thalamic nucleus in temporal lobe
seizures–an experimental study (Japanese-English abstract). Seishin Shinkeigaku
Zasshi 1969;71:63-82.
134 Gale K. Subcortical structures and pathways involved in convulsive
seizure generation. J Clin Neurophysiol 1992;9:264-77.
135 Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing
neurons in the human forebrain: comparison with D2 receptor expressing neurons.
Neuropsychopharmacology 1999;20:60-80.
136 Cohen BM, Wan W. The thalamus as a site of action of antipsychotic
drugs. Am J Psychiatry 1996;153:104-6.
137 Sun YJ, Suzuki M, Kurachi T, Murata M, Kurachi M. Expression of Fos
protein in the limbic regions of the rat following haloperidol decanoate.
Brain Res 1998;791:125-36.
138 Deutch AY, Ongur D, Duman RS. Antipsychotic drugs induce Fos protein
in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug
action. Neuroscience 1995;66:337-46.
139 Cohen BM, Wan W, Froimowitz MP, Ennulat DJ, Cherkerzian S, Konieczna H.
Activation of midline thalamic nuclei by antipsychotic drugs. Psychopharmacology
(Berlin) 1998;135:37-43.
140 Suzuki M, Sun YJ, Murata M, Kurachi M. Widespread expression of Fos
protein induced by acute haloperidol administration in the rat brain.
Psychiatry Clin Neurosci 1998;52:353-9.
141 Roe DL, Bardgett ME, Csernansky CA, Csernansky JG. Induction of Fos
protein by antipsychotic drugs in rat brain following kainic acid-induced
limbic-cortical neuronal loss. Psychopharmacology (Berlin) 1998;138:151-8.
142 Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Suzuki H, Kuroda S. Clozapine-
and olanzapine-induced Fos expression in the rat medial prefrontal cortex
is mediated by beta-adrenoceptors. Neuropsychopharmacology 2000;23:162-9.
143 Bubser M, Feenstra MG, Erdtsieck-Ernste EB, Botterblom MH, Van Uum HF,
Pool CW. Modulatory role of catecholamines in the transsynaptic expression
of c-fos in the rat medial prefrontal cortex induced by disinhibition of the
mediodorsal thalamus: a study employing microdialysis and immunohistochemistry.
Brain Res 1997;749:214-25.
144 Jones MW, Kilpatrick IC, Phillipson OT. Regulation of dopamine function
in the prefrontal cortex of the rat by the thalamic mediodorsal nucleus.
Brain Res Bull 1987;19:9-17.
145 Jones MW, Kilpatrick IC, Phillipson OT. Dopamine function in the prefrontal
cortex of the rat is sensitive to a reduction of tonic GABA-mediated inhibition
in the thalamic mediodorsal nucleus. Exp Brain Res 1988;69:623-34.
146 Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus
M. Mode of action of atypical neuroleptics in relation to the phencyclidine
model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism.
J Clin Psychopharmacol 1995;15:11S-18S.
147 Au-Young SM, Shen H, Yang CR. Medial prefrontal cortical output neurons
to the ventral tegmental area (VTA) and their responses to burst-patterned
stimulation of the VTA: neuroanatomical and in vivo electrophysiological analyses.
Synapse 1999;34:245-55.
148 Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal
fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.
Neurosci Lett 1980;20:379-82.
149 Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ.
Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1
and GluR2 in medial temporal lobe neurons in schizophrenia. Mol Brain
Res 1995;29:211-23.
150 Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the
human excitatory amino acid transporter 2 and metabotropic glutamate receptors
3 and 5 in the prefrontal cortex from normal individuals and patients with
schizophrenia. Mol Brain Res 1998;56:207-17.
151 Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic
glutamate receptors and expression of N-methyl-D-aspartate receptor subunits
in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry
2000;157:1141-9.
152 Akbarian S, Smith MA, Jones EG. Editing for an AMPA receptor subunit
RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's
disease and schizophrenia. Brain Res 1995;699:297-304.
153 Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, et
al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia.
J Neurochem 1989;52:1781-6.
154 Porter RH, Eastwood SL, Harrison PJ. Distribution of kainate receptor
subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral
reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain
Res 1997;751:217-31.
155 Eastwood SL, Burnet PW, Harrison PJ. GluR2 glutamate receptor subunit
flip and flop isoforms are decreased in the hippocampal formation in schizophrenia:
a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Mol
Brain Res 1997;44:92-8.
156 Grimwood S, Slater P, Deakin JF, Hutson PH. NR2B-containing NMDA receptors
are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999;10:461-5.
157 Dean B, Scarr E, Bradbury R, Copolov D. Decreased hippocampal (CA3)
NMDA receptors in schizophrenia. Synapse 1999;32:67-9.
158 Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, et
al. Selective alterations in gene expression for NMDA receptor subunits
in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.
159 Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective
loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia.
Biol Psychiatry 1991;29:41-54.
160 Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive
glycine binding sites in cerebral cortex of chronic schizophrenics: evidence
for glutamate hypothesis. Biol Psychiatry 1994;35:84-95.
161 Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of
glutamatergic deficiency in schizophrenia. Neurosci Lett 1991;121:77-80.
162 Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth
S, Pilc A. The role of glutamate receptors in antipsychotic drug action.
Amino Acids 2000;19:87-94.
163 Müller MJ, Grunder G, Wetzel H, Müller-Siecheneder F, Marx-Dannigkeit
P, Benkert O. Antipsychotic effects and tolerability of the sigma ligand
EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open
clinical trial. Psychiatry Res 1999;89:275-80.
164 Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A. Open clinical
trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology
(Berl) 1997;132:82-8.
165 Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein
M. Efficacy of high-dose glycine in the treatment of enduring negative
symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36 (comment
in: Arch Gen Psychiatry 1999;56:13-7).
166 Heresco-Levy U, Silipo G, Javitt DC. Glycinergic augmentation of NMDA
receptor-mediated neurotransmission in the treatment of schizophrenia.
Psychopharmacol Bull 1996;32:731-40.
167 Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind,
placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant
schizophrenia. Br J Psychiatry 1996;169:610-7.
168 Rosse RB, Schwartz BL, Davis RE, Deutsch SI. An NMDA intervention strategy
in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol
1991;14:268-72.
169 Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI. An open-label
trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin
Neuropharmacol 1990;13:348-54.
170 Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency
model of schizophrenia. Br J Psychiatry 1999;37:2-6.
171 Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging
role of glutamate mechanisms. Brain Res Rev 2000;31:302-12.
172 Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML. Rodent data
and general hypothesis: antipsychotic action exerted through 5-HT2A receptor
antagonism is dependent on increased serotonergic tone. J Neural Transm
1998;105:365-96.
173 Carlsson ML. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts
the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic
or muscarinic neurotransmission in the mouse – implications for psychosis.
J Neural Transm Gen Sect 1995;100:225-37.
174 Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, et
al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting
NMDA antagonist – than dopamine agonist-induced hyperactivity in mice.
J Neural Transm 1999;106:123-9.
175 Squires RF, Saederup E. A review of evidence for GABAergic predominance/glutamatergic
deficit as a common etiological factor in both schizophrenia and affective
psychoses: more support for a continuum hypothesis of "functional" psychosis.
Neurochem Res 1991;16:1099-111.
176 Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine:
from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
Neuropsychopharmacology 1999;20:201-25.
177 Halberstadt AL. The phencyclidine-glutamate model of schizophrenia.
Clin Neuropharmacol 1995;18:237-49.
178 Lourenço Neto F, Schadrack J, Berthele A, Zieglgansberger W, Tolle
TR, Castro-Lopes JM. Differential distribution of metabotropic glutamate
receptor subtype mRNAs in the thalamus of the rat. Brain Res 2000;854:93-105.
179 Liu XB. Subcellular distribution of AMPA and NMDA receptor subunit
immunoreactivity in ventral posterior and reticular nuclei of rat and cat
thalamus. J Comp Neurol 1997;388:587-602.
180 Spreafico R, Frassoni C, Arcelli P, Battaglia G, Wenthold RJ, De Biasi
S. Distribution of AMPA selective glutamate receptors in the thalamus of
adult rats and during postnatal development. A light and ultrastructural immunocytochemical
study. Dev Brain Res 1994;82:231-44.
181 Ohye C. Thalamus. In: Paxinos G, ed. The Human Nervous System.
San Diego (California): Academic Press 1990:439-68.
182 Quirion R, Pilapil C. Distribution of multiple opioid receptors in
the human brain. In: Mendelsohn FAO, Paxinos G, eds. Receptors in the
Human Nervous System. San Diego (California): Academic Press 1991:103-21.
183 von Bohlen, Halbach O, Albrecht D. Distribution of angiotensin II binding
sites in the mouse thalamus: receptor-binding study with fluorescent coupled
peptides and their conversion to a light stable product. Neuropeptides
1999;33:464-7.
184 Leresche N, Asprodini E, Emri Z, Cope DW, Crunelli V. Somatostatin
inhibits GABAergic transmission in the sensory thalamus via presynaptic receptors.
Neuroscience 2000;98:513-22.
185 Molinari M, Hendry SH, Jones EG. Distributions of certain neuropeptides
in the primate thalamus. Brain Res 1987;426:270-89.
186 Sohal VS, Cox CL, Huguenard JR. Localization of CCK receptors in thalamic
reticular neurons: a modeling study. J Neurophysiol 1998;79:2820-4.
187 Battaglia G, Colacitti C, Bentivoglio M. The relationship of calbindin-containing
neurons with substance P, Leu-enkephalin and cholecystokinin fibres: an immunohistochemical
study in the rat thalamus. J Chem Neuroanat 1992;5:453-64.
188 Sugimoto T, Itoh K, Yasui Y, Kaneko T, Mizuno N. Coexistence of neuropeptides
in projection neurons of the thalamus in the cat. Brain Res 1985;347:381-4.
189 Burgunder JM. La neuroanatomie chimique du thalamus: exemple de coexpression
de deux neuropeptides, cholecystokinine et peptide vasoactif intestinal.
Schweiz Med Wochenschr 1990;120:1180-5.
190 Durkin MM, Walker MW, Smith KE, Gustafson EL, Gerald C, Branchek TA. Expression
of a novel neuropeptide Y receptor subtype involved in food intake: an in
situ hybridization study of Y5 mRNA distribution in rat brain. Exp Neurol
2000;165:90-100.
191 Chiaia NL, Zhang Y, Chen M, Zhang S, Rhoades RW. Differential effects
of neuropeptide Y type 2 receptor activation on responses of rat ventral posteromedial
thalamus neurons to surround vibrissae and trigeminal subnucleus interpolaris
stimulation. Somatosens Mot Res 1997;14:295-300.
192 Morin LP, Blanchard JH. Neuropeptide Y and enkephalin immunoreactivity
in retinorecipient nuclei of the hamster pretectum and thalamus. Vis Neurosci
1997;14:765-77.
193 Takatsuji K, Tohyama M. Geniculo-geniculate projection of enkephalin
and neuropeptide Y containing neurons in the intergeniculate leaflet of the
thalamus in the rat. J Chem Neuroanat 1989;2:19-27.
194 Covenas R, Aguirre JA, Alonso JR, Dios M, Lara J, Aijon J. Distribution
of neuropeptide Y-like immunoreactive fibers in the cat thalamus. Peptides
1990;11:45-50.
195 Wan CP, Lau BH. Neuropeptide Y receptor subtypes. Life Sci 1995;56:1055-64.
196 Bouchard P, Monnet F, Bergeron R, Roman F, Junien JL, de Montigny C, et
al. In vivo modulation of sigma receptor sites by calcitonin gene-related
peptide in the mouse and rat hippocampal formation: radioligand binding and
electrophysiological studies. Eur J Neurosci 1995;7:1952-62.
197 Bouchard P, Roman F, Junien JL, Quirion R. Autoradiographic evidence
for the modulation of in vivo sigma receptor labeling by neuropeptide Y and
calcitonin gene-related peptide in the mouse brain. J Pharmacol Exp Ther
1996;276:223-30.
198 Ault DT, Radeff JM, Werling LL. Modulation of [3H]Dopamine release
from rat nucleus accumbens by neuropeptide Y may involve a sigma1-like receptor.
J Pharmacol Exp Ther 1998;284:553-60.
199 Ault DT, Werling LL. Neuropeptide Y-mediated enhancement of NMDA-stimulated
[3H]dopamine release from rat prefrontal cortex is reversed by sigma1 receptor
antagonists. Schizophr Res 1998;31:27-36.
200 Bouchard P, Maurice T, St-Pierre S, Privat A, Quirion R. Neuropeptide
Y and the calcitonin gene-related peptide attenuate learning impairments induced
by MK-801 via a sigma receptor-related mechanism. Eur J Neurosci 1997;9:2142-51.
201 Ault DT, Werling LL. Differential modulation of NMDA-stimulated [3H]dopamine
release from rat striatum by neuropeptide Y and sigma receptor ligands.
Brain Res 1997;760:210-7.
202 Ault DT, Werling LL. SH-SY5Y cells as a model for sigma receptor regulation
of potassium-stimulated dopamine release. Brain Res 2000;877:354-60.
203 Hoshino K, Hicks TP, Hirano S, Norita M. Ultrastructural organization
of transmitters in the cat lateralis medialis-suprageniculate nucleus of the
thalamus: an immunohistochemical study. J Comp Neurol 2000;419:257-70.
204 Vogt BA, Crino PB, Jensen EL. Multiple heteroreceptors on limbic thalamic
axons: M2 acetylcholine, serotonin1B, beta 2-adrenoceptors, mu-opioid, and
neurotensin. Synapse 1992;10:44-53.
205 Suzuki T, Moroji T, Hori T, Baba A, Kawai N, Koizumi J. Autoradiographic
localization of CCK-8 binding sites in the rat brain: effects of chronic methamphetamine
administration on these sites. Biol Psychiatry 1993;34:781-90.
206 Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al.
Neurotransmitters, receptors and neuropeptides in post-mortem brains of
chronic schizophrenic patients. Acta Psychiatr Scand 1988;78:121-37.
207 Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens DG, et al.
Peptides, the limbic lobe and schizophrenia. Brain Res 1983;288:199-211.
208 Andree TH, Gottesfeld Z, DeFrance JF, Sikes RW, Enna SJ. Evidence for
cholinergic muscarinic receptors on mediodorsal thalamic projections to the
anterior cingulate cortex. Neurosci Lett 1983;40:99-103.
209 Vogt LJ, Vogt BA, Sikes RW. Limbic thalamus in rabbit: architecture,
projections to cingulate cortex and distribution of muscarinic acetylcholine,
GABAA, and opioid receptors. J Comp Neurol 1992;319:205-17.
210 Kultas-Ilinsky K, Fogarty JD, Hughes B, Ilinsky IA. Distribution and
binding parameters of GABA and benzodiazepine receptors in the cat motor thalamus
and adjacent nuclear groups. Brain Res 1988;459:1-16.
211 Princivalle A, Regondi MC, Frassoni C, Bowery NG, Spreafico R. Distribution
of GABAB receptor protein in somatosensory cortex and thalamus of adult rats
and during postnatal development. Brain Res Bull 2000;52:397-405.
212 Trejo F, De la Vega MT, Arias-Montano JA. Functional characterisation
of alpha 1-adrenoceptor subtypes mediating noradrenaline-induced inositol
phosphate formation in rat thalamus slices. Eur J Pharmacol 1996;318:175-84.
213 Vlahov V, Bacracheva N. Effects of beta-adrenergic agents on the regional
cerebral blood flow in cortex and thalamus of the cat. Arch Int Pharmacodyn
Ther 1988;296:87-100.
214 Vlahov V, Bacracheva N. Effects of beta-adrenergic agents on the regional
cerebral blood flow in cortex and thalamus of the cat. Arch Int Pharmacodyn
Ther 1988;296:87-100.
215 Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G. Autoradiographic
localization of 5-HT2A receptors in the human brain using [3H]M100907 and
[11C]M100907. Synapse 2000;38:421-31.
216 Kakiuchi T, Nishiyama S, Sato K, Ohba H, Nakanishi S, Tsukada H. Age-related
reduction of [11C]MDL100,907 binding to central 5-HT2A receptors: PET study
in the conscious monkey brain. Brain Res 2000;883:135-42.
217 Scruggs JL, Patel S, Bubser M, Deutch AY. DOI-induced activation of
the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic
neurons. J Neurosci 2000;20:8846-52.
218 Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC. Immunohistochemical
localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology
2000;39:123-32.
219 Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, et al. Characterization
of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol
2000;130:539-48.
220 Gustafson EL, Durkin MM, Bard JA, Zgombick J, Branchek TA. A receptor
autoradiographic and in situ hybridization analysis of the distribution of
the 5-ht7 receptor in rat brain. Br J Pharmacol 1996;117:657-66.
221 Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et
al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated
in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-58.
222 To ZP, Bonhaus DW, Eglen RM, Jakeman LB. Characterization and distribution
of putative 5-ht7 receptors in guinea-pig brain. Br J Pharmacol 1995;115:107-16.
223 Olsen MA, Nawoschik SP, Schurman BR, Schmitt HL, Burno M, Smith DL, et
al. Identification of a human 5-HT6 receptor variant produced by alternative
splicing. Mol Brain Res 1999;64:255-63.
224 Waeber C, Moskowitz MA. [3H]sumatriptan labels both 5-HT1D and 5-HT1F
receptor binding sites in the guinea pig brain: an autoradiographic study.
Naunyn Schmiedebergs Arch Pharmacol 1995;352:263-75.
225 Bennett-Clarke CA, Leslie MJ, Chiaia NL, Rhoades RW. Serotonin 1B receptors
in the developing somatosensory and visual cortices are located on thalamocortical
axons. Proc Natl Acad Sci USA 1993;90:153-7.
226 Lotto B, Upton L, Price DJ, Gaspar P. Serotonin receptor activation
enhances neurite outgrowth of thalamic neurones in rodents. Neurosci
Lett 1999;269:87-90.
227 Young-Davies CL, Bennett-Clarke CA, Lane RD, Rhoades RW. Selective
facilitation of the serotonin1B receptor causes disorganization of thalamic
afferents and barrels in somatosensory cortex of rat. J Comp Neurol 2000;425:130-8.
228 Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions
and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-36.
229 Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine
withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia.
Neuropsychopharmacology 1999;21:195-202.
230 Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia:
clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-501.
231 Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic
cholinergic receptors in prefrontal cortices of medicated schizophrenics.
Life Sci 1983;33:2187-96.
232 Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic
receptor binding in subjects with schizophrenia: a study of the human hippocampal
formation. Biol Psychiatry 2000;48:381-838.
233 Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Muscarinic1 and 2
receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia.
Mol Psychiatry 2000;5:203-7.
234 Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density
of muscarinic M1 receptors is decreased in the caudate-putamen of subjects
with schizophrenia. Mol Psychiatry 1996;1:54-8 (comment by Reynolds
GP, ed. Muscarinic M1 receptors in schizophrenia. In: Mol Psychiatry
1996;1:364-6).
235 Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R. Serum
antibodies to nicotinic acetylcholine receptors in schizophrenic patients.
Schizophr Res 1994;12:131-6.
236 Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, et al.
Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 1994;2:179-92.
237 Matsuda K, Buckingham SD, Freeman JC, Squire MD, Baylis HA, Sattelle DB.
Effects of the alpha subunit on imidacloprid sensitivity of recombinant
nicotinic acetylcholine receptors. Br J Pharmacol 1998;123:518-24.
238 Tomizawa M, Casida JE. Minor structural changes in nicotinoid insecticides
confer differential subtype selectivity for mammalian nicotinic acetylcholine
receptors. Br J Pharmacol 1999;127:115-22.
239 Harvey SC, McIntosh JM, Cartier GE, Maddox FN, Luetje CW. Determinants
of specificity for alpha-conotoxin MII on alpha3beta2 neuronal nicotinic receptors.
Mol Pharmacol 1997;51:336-42.
240 Zwart R, Vijverberg HP. Potentiation and inhibition of neuronal nicotinic
receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol
1997;52:886-95.
241 Zwart R, Vijverberg HP. Four pharmacologically distinct subtypes of
alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes.
Mol Pharmacol 1998;54:1124-31.
242 Drew AE, Derbez AE, Werling LL. Nicotinic receptor-mediated regulation
of dopamine transporter activity in rat prefrontal cortex. Synapse 2000;38:10-6.
243 George TP, Verrico CD, Picciotto MR, Roth RH. Nicotinic modulation
of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization.
J Pharmacol Exp Ther 2000;295:58-66.
244 Albuquerque EX, Pereira EF, Mike A, Eisenberg HM, Maelicke A, Alkondon
M. Neuronal nicotinic receptors in synaptic functions in humans and rats:
physiological and clinical relevance. Behav Brain Res 2000;113:131-41.
245 Kaiser S, Wonnacott S. a-Bungarotoxin-sensitive nicotinic receptors
indirectly modulate [3H]dopamine release in rat striatal slices via glutamate
release. Mol Pharmacol 2000;58:312-8.
246 Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, et
al. UB-165: a novel nicotinic agonist with subtype selectivity implicates
the alpha4beta2* subtype in the modulation of dopamine release from rat striatal
synaptosomes. J Neurosci 2000;20:2783-91.
247 Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor
activation in human cerebral cortical interneurons: a mechanism for inhibition
and disinhibition of neuronal networks. J Neurosci 2000;20:66-75.
248 Albuquerque EX, Pereira EF, Braga MF, Matsubayashi H, Alkondon M. Neuronal
nicotinic receptors modulate synaptic function in the hippocampus and are
sensitive to blockade by the convulsant strychnine and by the anti-Parkinson
drug amantadine. Toxicol Lett 1998;102-103:211-8.
249 Alkondon M, Pereira EF, Barbosa CT, Albuquerque EX. Neuronal nicotinic
acetylcholine receptor activation modulates gamma-aminobutyric acid release
from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther 1997;283:1396-11.
250 Mameli-Engvall M, Schilström B, Svensson TH. Nicotine-induced
burst firing in ventral tegmental area dopamine neurons involves nitric oxide
synthesis. Abstract presented at the 6th Congress of the Italian Society
for Psychopathology (SOPSI), Rome, 21-25 February, 2001, Abstracts Book, Giornale
Italiano di Psicopatologia, in press.
251 Levey AI, Hallanger AE, Wainer BH. Cholinergic nucleus basalis neurons
may influence the cortex via the thalamus. Neurosci Lett 1987;74:7-13.
252 Buzsaki G, Bickford RG, Ponomareff G, Thal LJ, Mandel R, Gage FH. Nucleus
basalis and thalamic control of neocortical activity in the freely moving
rat. J Neurosci 1988;8:4007-26.
253 Metherate R, Ashe JH. Nucleus basalis stimulation facilitates thalamocortical
synaptic transmission in the rat auditory cortex. Synapse 1993;14:132-43.
254 Jourdain A, Semba K, Fibiger HC. Basal forebrain and mesopontine tegmental
projections to the reticular thalamic nucleus: an axonal collateralization
and immunohistochemical study in the rat. Brain Res 1989;505:55-65.
255 Spreafico R, Amadeo A, Angoscini P, Panzica F, Battaglia G. Branching
projections from mesopontine nuclei to the nucleus reticularis and related
thalamic nuclei: a double labelling study in the rat. J Comp Neurol 1993;336:481-92.
256 Grunwerg BS, Krein H, Krauthamer GM. Somatosensory input and thalamic
projection of pedunculopontine tegmental neurons. Neuroreport 1992;3:673-5.
257 Erro E, Lanciego JL, Gimenez-Amaya JM. Relationships between thalamostriatal
neurons and pedunculopontine projections to the thalamus: a neuroanatomical
tract-tracing study in the rat. Exp Brain Res 1999;127:162-70.
258 Petrovicky P, Nemcová V. Differences in the NADPH-diaphorase
positivity of the cholinergic brain stem neurons following damage of theirs
thalamic termination field. Sb Lek 2000;101:131-42.
259 Curro Dossi R, Pare D, Steriade M. Short-lasting nicotinic and long-lasting
muscarinic depolarizing responses of thalamocortical neurons to stimulation
of mesopontine cholinergic nuclei. J Neurophysiol 1991;65:393-406.
260 Nemcová V, Petrovicky P, ten Donkelaar HJ. The effect of electrolytic
thalamic lesions on the NADPH-diaphorase activity of neurons of the laterodorsal
tegmental and pedunculopontine nuclei in rats. J Chem Neuroanat 2000;17:227-32.
261 Roth MT, Fleegal MA, Lydic R, Baghdoyan HA. Pontine acetylcholine release
is regulated by muscarinic autoreceptors. Neuroreport 1996;7:3069-72.
262 Thakkar MM, Strecker RE, McCarley RW. Behavioral state control through
differential serotonergic inhibition in the mesopontine cholinergic nuclei:
a simultaneous unit recording and microdialysis study. J Neurosci 1998;18:5490-7.
263 Steininger TL, Wainer BH, Blakely RD, Rye DB. Serotonergic dorsal raphe
nucleus projections to the cholinergic and noncholinergic neurons of the pedunculopontine
tegmental region: a light and electron microscopic anterograde tracing and
immunohistochemical study. J Comp Neurol 1997;382:302-22.
264 Futami T, Takakusaki K, Kitai ST. Glutamatergic and cholinergic inputs
from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia
nigra pars compacta. Neurosci Res 1995;21:331-42.
265 Fujimoto K, Ikeguchi K, Yoshida M. Decrease and recovery of choline
acetyltransferase activity in medial thalamus and ventral tegmental area after
destruction of pedunculopontine nucleus areas in the rat. Neurosci Res
1990;9:48-53.
266 Klitenick MA, Kalivas PW. Behavioral and neurochemical studies of opioid
effects in the pedunculopontine nucleus and mediodorsal thalamus. J Pharmacol
Exp Ther 1994;269:437-48.
267 Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation,
antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995;12:3-16.
268 Garcia-Rill E, Biedermann JA, Chambers T, Skinner RD, Mrak RE, Husain
M, et al. Mesopontine neurons in schizophrenia. Neuroscience 1995;66:321-35.
269 Karson CN, Garcia-Rill E, Biedermann J, Mrak RE, Husain MM, Skinner RD.
The brain stem reticular formation in schizophrenia. Psychiatry Res
1991;40:31-48.
270 German DC, Manaye KF, Wu D, Hersh LB, Zweig RM. Mesopontine cholinergic
and non-cholinergic neurons in schizophrenia. Neuroscience 1999;94:33-8.
271 Adem A, Jossan SS, d'Argy R, Brandt I, Winblad B, Nordberg A. Distribution
of nicotinic receptors in human thalamus as visualized by 3H-nicotine and
3H-acetylcholine receptor autoradiography. J Neural Transm 1988;73:77-83.
272 Rubboli F, Court JA, Sala C, Morris C, Chini B, Perry E, et al. Distribution
of nicotinic receptors in the human hippocampus and thalamus. Eur J Neurosci
1994;6:1596-604.
273 Bina KG, Guzman P, Broide RS, Leslie FM, Smith MA, O'Dowd DK. Localization
of alpha 7 nicotinic receptor subunit mRNA and alpha-bungarotoxin binding
sites in developing mouse somatosensory thalamocortical system. J Comp
Neurol 1995;363:321-32.
274 Broide RS, O'Connor LT, Smith MA, Smith JA, Leslie FM. Developmental
expression of alpha 7 neuronal nicotinic receptor messenger RNA in rat sensory
cortex and thalamus. Neuroscience 1995;67:83-94.
275 Broide RS, Robertson RT, Leslie FM. Regulation of alpha7 nicotinic
acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical
afferents. J Neurosci 1996;16:2956-71.
276 Lavine N, Reuben M, Clarke PB. A population of nicotinic receptors
is associated with thalamocortical afferents in the adult rat: laminal and
areal analysis. J Comp Neurol 1997;380:175-90.
277 Gioanni Y, Rougeot C, Clarke PB, Lepouse C, Thierry AM, Vidal C. Nicotinic
receptors in the rat prefrontal cortex: increase in glutamate release and
facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci
1999;11:18-30.
278 Bullock AE, Clark AL, Grady SR, Robinson SF, Slobe BS, Marks MJ, et al.
Neurosteroids modulate nicotinic receptor function in mouse striatal and
thalamic synaptosomes. J Neurochem 1997;68:2412-23.
279 Spurden DP, Court JA, Lloyd S, Oakley A, Perry R, Pearson C, et al. Nicotinic
receptor distribution in the human thalamus: autoradiographical localization
of [3H]nicotine and [125I] alpha-bungarotoxin binding. J Chem Neuroanat
1997;13:105-13.
280 Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, et al.
Comparison of the regional expression of nicotinic acetylcholine receptor
alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain.
J Comp Neurol 1997;387:385-98.
281 Quik M, Polonskaya Y, Gillespie A, Jakowec M, Lloyd GK, Langston JW. Localization
of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization.
J Comp Neurol 2000;425:58-69.
282 Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, Baldwin RM, Seibyl JP,
et al. Measurement of alpha4beta2 nicotinic acetylcholine receptors with
[123I]5-I-A-85380 SPECT. J Nucl Med 2000;41:1552-60.
283 Sahin M, Bowen WD, Donoghue JP. Location of nicotinic and muscarinic
cholinergic and mu-opiate receptors in rat cerebral neocortex: evidence from
thalamic and cortical lesions. Brain Res 1992;579:135-47.
284 Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, et al.
Smoking and schizophrenia: abnormal nicotinic receptor expression.
Eur J Pharmacol 2000;393:237-42.
285 Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain
tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.
Biol Psychiatry 1995;38:22-33.
286 Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, et al.
Nicotinic receptor function in schizophrenia. Schizophr Bull 1996;22:431-45.
287 Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of
nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic
brain. Neuroreport 1999;10:1779-82.
288 Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic
receptor desensitization and sensory gating deficits in schizophrenia.
Biol Psychiatry 1998;44:98-106.
289 Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, et al.
Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull
1998;24:189-202.
290 Grottick AJ, Wyler R, Higgins GA. The alpha4beta2 agonist SIB 1765F,
but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant
effects of nicotine. Psychopharmacology (Berl) 2000;150:233-6.
291 Buisson B, Vallejo YF, Green WN, Bertrand D. The unusual nature of
epibatidine responses at the alpha4beta2 nicotinic acetylcholine receptor.
Neuropharmacology 2000;39:2561-9.
292 Durany N, Zochling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, et
al. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor
density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000;287:109-12.
293 Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, et al. Abnormal
regulation of high affinity nicotinic receptors in subjects with schizophrenia.
Neuropsychopharmacology 2000;23:351-64.
294 Miyaoka T, Seno H, Ishino H. Increased expression of Wnt-1 in schizophrenic
brains. Schizophr Res 1999;38:1-6.
295 Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S, et
al. Abnormalities of Wnt signalling in schizophrenia--evidence for neurodevelopmental
abnormality. Neuroreport 1998;9:1379-83.
296 Stober G, Syagailo YV, Okladnova O, Jungkunz G, Knapp M, Beckmann H, et
al. Functional PAX-6 gene-linked polymorphic region: potential association
with paranoid schizophrenia. Biol Psychiatry 1999;45:1585-91.
297 Rodriguez MA, Pesold C, Liu WS, Kriho V, Guidotti A, Pappas GD, et al.
Colocalization of integrin receptors and reelin in dendritic spine postsynaptic
densities of adult nonhuman primate cortex. Proc Natl Acad Sci USA 2000;97:3550-5.
298 Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, et al.
Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression
in schizophrenia and bipolar disorder: A postmortem brain study. Arch
Gen Psychiatry 2000;57:1061-9.
299 Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG,
et al. A decrease of reelin expression as a putative vulnerability factor
in schizophrenia. Proc Natl Acad Sci USA 1998;95:15718-23.
300 Alcantara S, Ruiz M, D'Arcangelo G, Ezan F, de Lecea L, Curran T, et al.
Regional and cellular patterns of reelin mRNA expression in the forebrain
of the developing and adult mouse. J Neurosci 1998;18:7779-99.
301 Braisted JE, Catalano SM, Stimac R, Kennedy TE, Tessier-Lavigne M, Shatz
CJ, et al. Netrin-1 promotes thalamic axon growth and is required for proper
development of the thalamocortical projection. J Neurosci 2000;20:5792-801.
302 Bolz J, Castellani V, Mann F, Henke-Fahle S. Specification of layer-specific
connections in the developing cortex. Prog Brain Res 1996;108:41-54.
303 Sitskoorn MM, Appels MC, Hulshoff Pol HE, Kahn RS. Evidence of fronto-thalamic
involvement in schizophrenia. Prog Brain Res 2000;126:343-55.
304 Hulshoff Pol HE, van der Flier WM, Schnack HG, Tulleken CA, Ramos LM,
van Ree JM, et al. Frontal lobe damage and thalamic volume changes.
Neuroreport 2000;11:3039-41.
305 Armstrong E. Limbic thalamus: anterior and mediodorsal nuclei.
In: Paxinos G, ed. The Human Nervous System. San Diego (California):
Academic Press 1990:469-81.
306 Voogd J, Nieuwenhuys R, van Dongen PAM, ten Donkelaar HJ. Mammals.
In: Nieuwenhuys R, ten Donkelaar HJ, Nicholson C, eds. The Central Nervous
System of Vertebrates. Berlin: Springer Verlag 1998;vol.3:1636-2097.
307 Gonzalo-Ruiz A, Sanz JM, Morte L, Lieberman AR. Glutamate and aspartate
immunoreactivity in the reciprocal projections between the anterior thalamic
nuclei and the retrosplenial granular cortex in the rat. Brain Res Bull
1997;42:309-21.
308 Hirsch MC. Functional Systems. Thalamocortical projections. Berlin:
Springer Verlag 1998;InterBrain5,fig.167.
309 Ahmed AK, Dong K, Sugioka K, Yamadori T. Afferent projections to the
cingulate cortex in albino rats: a study with a retrograde labeling method
using fluoro-gold. Kobe J Med Sci 1995;41:247-55.
310 Shibata H. Efferent projections from the anterior thalamic nuclei to
the cingulate cortex in the rat. J Comp Neurol 1993;330:533-42.
311 Horikawa K, Kinjo N, Stanley LC, Powell EW. Topographic organization
and collateralization of the projections of the anterior and laterodorsal
thalamic nuclei to cingulate areas 24 and 29 in the rat. Neurosci Res
1988;6:31-44.
312 Vogt BA, Pandya DN, Rosene DL. Cingulate cortex of the rhesus monkey:
I. Cytoarchitecture and thalamic afferents. J Comp Neurol 1987;262:256-70.
313 Matsuoka H. Topographic arrangement of the projection from the anterior
thalamic nuclei to the cingulate cortex in the cat. Neurosci Res 1986;4:62-6.
314 Niimi K, Niimi M, Okada Y. Thalamic afferents to the limbic cortex
in the cat studied with the method of retrograde axonal transport of horseradish
peroxidase. Brain Res 1978;145:225-38.
315 Niimi M. Cortical projections of the anterior thalamic nuclei in the
cat. Exp Brain Res 1978;31:403-16.
316 Oda S. Ultrastructure and distribution of corticothalamic fiber terminals
from the posterior cingulate cortex and the presubiculum to the anteroventral
thalamic nucleus of the rat. Brain Res Bull 1997;42:485-91.
317 Seki M, Zyo K. Anterior thalamic afferents from the mamillary body
and the limbic cortex in the rat. J Comp Neurol 1984;229:242-56.
318 Bayer SA. Neurogenetic patterns in the medial limbic cortex of the
rat related to anatomical connections with the thalamus and striatum.
Exp Neurol 1990;107:132-42.
319 Szeszko PR, Bilder RM, Lencz T, Ashtari M, Goldman RS, Reiter G, et al.
Reduced anterior cingulate gyrus volume correlates with executive dysfunction
in men with first-episode schizophrenia. Schizophr Res 2000;43:97-108.
320 Benes FM. Evidence for neurodevelopment disturbances in anterior cingulate
cortex of post-mortem schizophrenic brain. Schizophr Res 1991;5:187-8.
321 Benes FM, Bird ED. An analysis of the arrangement of neurons in the
cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987;44:608-16.
322 Benes FM, Majocha R, Bird ED, Marotta CA. Increased vertical axon numbers
in cingulate cortex of schizophrenics. Arch Gen Psychiatry 1987;44:1017-21.
323 Benes FM, McSparren J, Bird ED, San Giovanni JP, Vincent SL. Deficits
in small interneurons in prefrontal and cingulate cortices of schizophrenic
and schizoaffective patients. Arch Gen Psychiatry 1991;48:996-1001.
324 Gabriel M, Miller JD, Saltwick SE. Unit activity in cingulate cortex
and anteroventral thalamus of the rabbit during differential conditioning
and reversal. J Comp Physiol Psychol 1977;91:423-33.
325 Gabriel M, Foster K, Orona E. Interaction of laminae of the cingulate
cortex with the anteroventral thalamus during behavioral learning. Science
1980;208:1050-2.
326 Foster K, Orona E, Lambert RW, Gabriel M. Early and late acquisition
of discriminative neuronal activity during differential conditioning in rabbits:
specificity within the laminae of cingulate cortex and the anteroventral thalamus.
J Comp Physiol Psychol 1980;94:1069-86.
327 Gabriel M, Orona E. Parallel and serial processes of the prefrontal
and cingulate cortical systems during behavioral learning. Brain Res Bull
1982;8:781-5.
328 Gabriel M, Lambert RW, Foster K, Orona E, Sparenborg S, Maiorca RR. Anterior
thalamic lesions and neuronal activity in the cingulate and retrosplenial
cortices during discriminative avoidance behavior in rabbits. Behav Neurosci
1983;97:675-96.
329 Sparenborg S, Gabriel M. Neuronal encoding of conditional stimulus
duration in the cingulate cortex and the limbic thalamus of rabbits. Behav
Neurosci 1990;104:919-33.
330 ogt BA, Gabriel M, Vogt LJ, Poremba A, Jensen EL, Kubota Y, et al. Muscarinic
receptor binding increases in anterior thalamus and cingulate cortex during
discriminative avoidance learning. J Neurosci 1991;11:1508-14.
331 Noga JT, Aylward E, Barta PE, Pearlson GD. Cingulate gyrus in schizophrenic
patients and normal volunteers. Psychiatry Res 1995;61:101-8.
332 Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA, et al.
Effects of age, medication, and illness duration on the N-acetyl aspartate
signal of the anterior cingulate region in schizophrenia. Schizophr Res
2000;41:389-95.
333 Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic resonance
spectroscopy of the anterior cingulate region in schizophrenia. Schizophr
Res 1997;27:65-71.
334 Wyatt RJ, Karoum F, Casanova MF. Decreased DOPAC in the anterior cingulate
cortex of individuals with schizophrenia. Biol Psychiatry 1995;38:4-12
(comment in: Biol Psychiatry 1996;39:464-5).
335 Benes FM, Vincent SL, Alsterberg G, Bird ED, San Giovanni JP. Increased
GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics.
J Neurosci 1992;12:924-9.
336 Squires RF, Lajtha A, Saederup E, Palkovits M. Reduced [3H]flunitrazepam
binding in cingulate cortex and hippocampus of postmortem schizophrenic brains:
is selective loss of glutamatergic neurons associated with major psychoses?
Neurochem Res 1993;18:219-23.
337 Benes FM, Sorensen I, Vincent SL, Bird ED, Sathi M. Increased density
of glutamate-immunoreactive vertical processes in superficial laminae in cingulate
cortex of schizophrenic brain. Cereb Cortex 1992;2:503-12.
338 Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P,
et al. Increased concentrations of presynaptic proteins in the cingulate
cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997;54:559-66
(erratum in Arch Gen Psychiatry 1997;54:912).
339 Honer WG, Falkai P, Young C, Wang T, Xie J, Bonner J, et al. Cingulate
cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia.
Neuroscience 1997;78:99-110.
340 Haznedar MM, Buchsbaum MS, Luu C, Hazlett EA, Siegel BV Jr, Lohr J, et
al. Decreased anterior cingulate gyrus metabolic rate in schizophrenia.
Am J Psychiatry 1997;154:682-4.
341 Carter CS, Mintun M, Nichols T, Cohen JD. Anterior cingulate gyrus
dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET
study during single-trial Stroop task performance. Am J Psychiatry 1997;154:1670-5
(comment by Spence SA. More stringent threshold needed. In: Am J Psychiatry
1999;156:803-4, with authors’ response in Am J Psychiatry 1999;158:804).
342 Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM.
Dopaminergic modulation of impaired cognitive activation in the anterior
cingulate cortex in schizophrenia. Nature 1995;378:180-2.
343 Tamminga CA, Vogel M, Gao X, Lahti AC, Holcomb HH. The limbic cortex
in schizophrenia: focus on the anterior cingulate. Brain Res Rev 2000;31:364-70.
344 Benes FM. Emerging principles of altered neural circuitry in schizophrenia.
Brain Res Rev 2000;31:251-69.
345 Benes FM. Alterations of neural circuitry within layer II of anterior
cingulate cortex in schizophrenia. J Psychiatr Res 1999;33:511-2.
346 Benes FM, Todtenkopf MS, Taylor JB. Differential distribution of tyrosine
hydroxylase fibers on small and large neurons in layer II of anterior cingulate
cortex of schizophrenic brain. Synapse 1997;25:80-92.
347 Benes FM. Model generation and testing to probe neural circuitry in
the cingulate cortex of postmortem schizophrenic brain. Schizophr Bull
1998;24:219-30.
348 Benes FM. Altered glutamatergic and GABAergic mechanisms in the cingulate
cortex of the schizophrenic brain. Arch Gen Psychiatry 1995;52:1015-8;
discussion 1019-24.
349 Klawans HL, Margolin DI. Amphetamine-induced dopaminergic hypersensitivity
in guinea pigs. Implications in psychosis and human movement disorders.
Arch Gen Psychiatry 1975;32:725-32.
350 Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A,
et al. Schizophrenia is associated with elevated amphetamine-induced synaptic
dopamine concentrations: evidence from a novel positron emission tomography
method. Proc Natl Acad Sci USA 1997;94:2569-74.
351 Kapit RM. Schizophrenia and tardive dyskinesia: is schizophrenia also
a "denervation hypersensitivity"? Med Hypotheses 1977;3:207-10.
352 Fletcher P, McKenna PJ, Friston KJ, Frith CD, Dolan RJ. Abnormal cingulate
modulation of fronto-temporal connectivity in schizophrenia. Neuroimage
1999;9:337-42.
353 Smythies G. The functional neuroanatomy of awareness: with a focus
on the role of various anatomical systems in the control of intermodal attention.
Conscious Cogn 1997;6:455-81.
354 Alkire MT, Haier RJ, Fallon JH. Toward a unified theory of narcosis:
brain imaging evidence for a thalamocortical switch as the neurophysiological
basis of anesthetic-induced unconsciousness. Conscious Cogn 2000;9:370-86.
355 Metzinger T. Subject und Selbstmodell. Paderborn: Schoningh Verlag
1993.
356 Ben Shalom D. Developmental depersonalization: the prefrontal cortex
and self-functions in autism. Conscious Cogn 2000;9:457-60.